Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin detemir Clear all
Completed Phase 3 Interventional Results available

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

NCT02302716
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2963016, LANTUS®, Oral Antihyperglycemic Medication
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Miami, Florida • New Port Richey, Florida • Smyrna, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes

NCT00097084
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
28
States / cities
Little Rock, Arkansas • Inglewood, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

NCT00659165
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Detemir, Insulin Glargine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

NCT01011868
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773 placebo, BI 10773 low dose, BI 10773 high dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

NCT00998335
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

NCT02451137
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300 U/ml, Insulin glargine, 100 U/ml, Insulin detemir, Background Therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
407
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

NCT00856986
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, insulin detemir, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 84 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
60
States / cities
Alexander City, Alabama • Birmingham, Alabama • Encino, California + 49 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

NCT02518945
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 17, 2026, 9:16 AM EDT
Terminated Not applicable Interventional

Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis

NCT03001323
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Degludec, Standard long-acting
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

NCT01076842
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Insulin-Levemir, Exenatide-Bayetta, Insulin-Levemir and Exenatide-Bayetta, SenseWear Pro3® armband, DexCom CGM
Drug · Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 17, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)

NCT06419803
View directory record Official record
Conditions
Gestational Diabetes, Pregnancy Related
Interventions
Insulin
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Study of Glycemic Control on Liver Transplantation Outcomes

NCT01211730
View directory record Official record
Conditions
Evidence of Liver Transplantation, Hyperglycemia, Rejection
Interventions
Insulin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

NCT01831765
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
116
States / cities
Mobile, Alabama • Tucson, Arizona • Anaheim, California + 87 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01835431
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec/insulin aspart, insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes

NCT00467649
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pramlintide acetate (Symlin), rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine]), basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
37
States / cities
Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

NCT00106366
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
68
States / cities
Birmingham, Alabama • Vestavia Hills, Alabama • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir

NCT00717288
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Detemir
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily

NCT00634842
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
66
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Searcy, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

NCT00283751
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
21
States / cities
Greenbrae, California • La Mesa, California • West Palm Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes

NCT01232491
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
Insulin detemir, Dietary regimen
Drug · Dietary Supplement
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Birmingham, Alabama • Ozark, Alabama • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Cystic Fibrosis - Insulin Deficiency, Early Action

NCT01100892
View directory record Official record
Conditions
Cystic Fibrosis, Diabetes
Interventions
Once-daily insulin detemir
Drug
Lead sponsor
Sydney Children's Hospitals Network
Other
Eligibility
5 Years to 19 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 17, 2026, 9:16 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes

NCT02811484
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
Drug · Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 17, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01513473
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 17 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 17, 2026, 9:16 AM EDT